ALISO VIEJO, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCQB:CNSO)
CNS Response CEO George Carpenter and CFO Paul Buck are hosting a webinar and live question and answer session for investors this Thursday, December 11, 2014, at 4:10 p.m. ET. The webinar will provide insight into the Company's recent achievements and key revenue drivers for its unique mental health technology.
The Company's PEER (Psychiatric EEG Evaluation Registry) technology is a clinical registry and recommendation engine which provides physicians with objective information on medication response for mental health patients. Previous PEER trials have demonstrated that doctors with more information achieve better outcomes, with less reliance on trial and error.
An ongoing clinical trial with the US military has produced promising early results, which were highlighted during recent congressional testimony in support of the Clay Hunt Suicide Prevention for American Veterans Act (HR 5059).
"We are gratified the House has unanimously passed this legislation, and look forward to the increased transparency and accountability it will bring to military medicine," said Carpenter. "The VA and the DoD have spent $9.3 billion on research and treatment of PTSD, according to the June Institute of Medicine report and yet we will never know which interventions worked because outcomes weren't systematically collected. It's time for an outcome registry like PEER, to help the physicians who help our veterans."
In addition to its success with its U.S. military clinical trial, CNS Response is seeing growing consumer adoption of its PEER technology, driven by an algorithm-based rich marketing automation program that promises predictable and scalable growth.
Carpenter continued, "Much like our PEER technology, our consumer marketing program leverages big data to improve performance. We are able to geographically target the right patients with the right attributes across a variety of online media platforms. This gives the consumer the opportunity to lead the adoption process through an intuitive web-based format allowing us to reduce our marketing costs by as much as 80%, all while seeing higher closing ratios for new patient acquisitions."
To participate in Thursday's event visit:
http://www.redchip.com/special_event/watch/cnso_12112014
About CNS Response Inc.
CNS Response (www.cnsresponse.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company's Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 37,350 outcomes for over 9,900 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, which is the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response representatives at PEERinfo@cnsresponse.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.